CU
Therapeutic Areas
Ochre Bio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OB-220 | Significant Fibrosis | Preclinical |
| Undisclosed Metabolic Program | Cirrhosis (F4 MASH) | Preclinical |
| Undisclosed Multiple Mechanism Program | Significant Fibrosis | Discovery |
| Undisclosed Regeneration Program | Cirrhosis | Discovery |